Skip to main content

Table 1 Characteristics of the study population at T2, n(%), mean±SD

From: Is kallikrein-8 a blood biomarker for detecting amnestic mild cognitive impairment? Results of the population-based Heinz Nixdorf Recall study

 

aMCI

n=37

CU

n=72

Total

n=109

p-values

KLK8, pg/ml

911.6±619.8

783.1±633.0

826.7±628.7

0.24

Sex

23 (62.2)

 

69 (63.3)

0.86

Men

46 (63.9)

 

Women

14 (37.8)

26 (36.1)

40 (36.7)

 

Age, years

70.9±8.2

71.0±7.9

71.0±8.0

0.97

BMI, kg/m2

29.2±5.3

28.1±3.3

28.5±4.1

0.36

Years of education

14.0±2.4

14.7±2.4

14.5±2.4

0.20

Smoking status

16 (43.2)

 

49 (45.0)

0.82

Never

33 (45.8)

 

Past

17 (45.9)

29 (40.3)

46 (42.2)

 

Current

4 (10.8)

10 (13.9)

14 (12.8)

 

Sports

18 (48.6)

 

49 (45.0)

0.58

No

31 (43.1)

 

Yes

19 (51.4)

41 (56.9)

60 (55.0)

 

APOE ε4 positive

   

0.01

No

17 (45.9)

52 (72.2)

69 (63.3)

 

Yes

18 (48.6)

19 (26.4)

37 (33.9)

 

Missing

2 (5.4)

1 (1.4)

3 (2.8)

 

z score attention

9.5±4.2

11.3±1.8

10.7±2.9

0.02

z score executive function

8.7±3.7

11.3±1.8

10.4±2.9

<.01

z score verbal memory

5.9±1.1

11.2±2.3

9.4±3.2

<.01

z score visuoconstruction

10.3±2.7

11.2±1.9

10.9±2.3

0.11

Depressiona

6 (16.2)

0

6 (5.5)

<.01

Missing

2 (5.4)

3 (4.2)

5

 

Hypertension

   

0.82

No

27 (73.0)

54 (75.0)

81 (74.3)

 

Yes

10 (27.0)

18 (25.0)

28 (25.7)

 

Diabetes mellitus

   

0.54

No

32 (86.5)

59 (81.9)

91 (83.5)

 

Yes

5 (13.5)

13 (18.1)

18 (16.5)

 

Freezing duration, years

7.5±1.0

8.3±0.7

8.0±0.9

<.01

  1. T2 ten-year follow-up, SD standard deviation, aMCI amnestic mild cognitive impairement, CU cognitive unimpaired, KLK8 kallikrein 8, BMI body mass index, APOE ε4 Apolipoprotein E ε4
  2. a Elevated depressive symptoms (CES-D≥18)